Sergio Cantoreggi

Helsinn Holding SA is a holding Swiss company that provides cancer services through its subsidiaries. The private company is based in Lugano, Switzerland and has subsidiaries in Switzerland and Ireland. The company was founded in 1976 by Gabriele Edoardo Braglia. Riccardo Braglia has been the CEO of the company since 2002.

3B FUTURE HEALTH VENTURES SARL (3B Future Health Ventures) is a venture capital subsidiary of Helsinn Healthcare SA founded in 2016. The firm is headquartered in Monaco, Luxembourg.

Helsinn Therapeutics (U.S.), Inc. develops, manufactures and supplies pharmaceutical products for treatment of cancer. The company is headquartered in Iselin. NJ.

QuantuMDx Group Ltd. develops devices for diagnostics detection. The firm offers DNA-XT, Under The Tree Diagnostics, Q-POC, and Internet of Life. The company was founded by Jonathan O'Halloran, Elaine Warburton, and Julian Warburton in March 2008 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Greenbone Ortho SRL develops a wood-derived bone implants technology to generate biomimetic implant suitable to address non-union fractures. It offers GreenBone that reproduce chemical composition and thee-dimensional architecture of natural tissues. The company was founded by Lorenzo Pradella in 2014 and is headquartered in Faenza, Italy.

Diadem Srl predicts, monitors, diagnosis and drug development for Alzheimer?s disease. focuses on specific research on early peripheral markers of Alzheimer's disease into technology. The company was founded by Maurizio Memo and Daniela Uberti in June 2012 and is headquartered in Brescia, Italy.

Micromega Ltd. provides business support services. The private company is based in London, UK. The British company was founded by Francesco Granata.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.

BSP Pharmaceuticals SpA develops and manufactures anticancer drugs. It offers development, clinical supply, commercial supply, and analytical services. The company was founded by Aldo Braca in July 2006 and is headquartered in Latina Scalo, Italy.

Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom.

Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom.

Italfarmaco SpA engages in the production and distribution of pharmaceutical and fine chemical products. It also provides research and development, scientific publishing, business development, and licensing services. The company was founded in 1938 and is headquartered in Milan, Italy.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

FSI SGR SpA (FSI) also known as Fondo Strategico Italiano, is an independent private equity firm. The firm was founded in 2016 and is headquartered in Milan, Italy.

Prismic Pharmaceuticals, Inc. engages in the research and development of prescription drugs for kidney disease, mental health, and chronic pain. It also offers medical foods for patients with chronic kidney disease, and depression and bipolar disorder. The company was founded by Zachary Dutton, Danilo Casadei Massari, and Peter J. Moriarty in 2011 and is headquartered in Worcester, MA.

New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY.

3B Future Health Fund II S.C. A. SICAV-RAIF invests in companies located in the US, Europe, Israel and Japan. The fund target companies operating in the fields of healthcare. It provides financing for early stage capital requirements with an investment up to USD 12 million. It also makes follow on investment and take a seat on the board of director.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland.

The National Centre for Research and Development in Poland provides executive agency services.

AAAS Fellowship Programs, Inc. provides health insurance services. The company is headquartered in Washington, DC.

Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden.

Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Bär & Karrer is a leading Swiss law firm. They advise its clients on a broad range of business law issues. They are committed to delivering prompt advice and innovative solutions to its clients. With more than 120 lawyers they regularly handle complex transactions and litigation providing a flexible and individualized service. For every project, they use specialized teams in order to efficiently assist its clients. They serve clients ranging from multinational corporations to private individuals both in Switzerland and globally. In a global economy, legal issues rarely stop at national boundaries; as a result, the majority of its work has an international component. They have an extensive international network of correspondent law firms, which are market leaders in their jurisdiction. They have offices in the three main language areas of Switzerland (Zurich, Zug, Lugano and Geneva).